← 返回

妊娠期乳腺癌作为早发性乳腺癌的特殊类型:肿瘤免疫微环境与风险特征分析

英文原题:Breast Cancer during Pregnancy as a Special Type of Early-Onset Breast Cancer: Analysis of the Tumor Immune Microenvironment and Risk Profiles.

查看英文原题

Breast Cancer during Pregnancy as a Special Type of Early-Onset Breast Cancer: Analysis of the Tumor Immune Microenvironment and Risk Profiles.

PubMed 2022/07/24(内容时间) Cells Q2 · IF 6(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

妊娠期乳腺癌(PrBC)较罕见,其免疫图谱研究有限。本研究旨在描述PrBC肿瘤微环境(TME)的细胞组成,并确定其与非妊娠女性早发乳腺癌(EOBC)的差异。从本机构登记病例中选取83例PrBC和89例EOBC,分析TIL(肿瘤浸润淋巴细胞)特征,并对CD4、CD8、叉头框P3(FOXP3)和程序性死亡配体1(PD-L1,22C3克隆)进行免疫组化检测。PrBC中激素受体(HR)阳性肿瘤比例显著较低。与对照组相比,PrBC中PD-L1低表达或阴性及CD8阳性TIL低表达/缺失更常见,尤其是在HR阳性/HER2阴性乳腺癌中。与EOBC相比,PrBC复发和疾病相关死亡风险显著较高。TIL存在及各TIL亚群均与疾病复发显著相关。

此外,存在CD8阳性TIL的PrBC患者死亡率较高。PrBC的TME具有特定TIL亚群模式,并具有重要生物学和预后意义。常规评估TIL及其亚型可作为病理报告的有效补充,帮助识别具有临床意义的PrBC女性患者亚群。

展开英文摘要原文

Breast cancer during pregnancy (PrBC) is a rare tumor with only a little information on its immune landscape.

Here, we sought to characterize the cellular composition of the tumor microenvironment (TME) of PrBC and identify its differences from early-onset breast cancer (EOBC) in non-pregnant women. A total of 83 PrBC and 89 EOBC were selected from our Institutional registry and subjected to tumor-infiltrating lymphocytes (TILs) profiling and immunohistochemistry for CD4, CD8, forkhead box P3 (FOXP3), and programmed death-ligand 1 (PD-L1) (clone 22C3).

A significantly lower frequency of hormone receptor (HR)-positive tumors was observed in PrBC. The prevalence of low/null PD-L1 and CD8+TILs was higher in PrBC than in the controls, specifically in HR+/HER2- breast cancers. PrBC had a significantly higher risk of relapse and disease-related death, compared to EOBC. The presence of TILs and each TIL subpopulation were significantly associated with disease relapse.

Moreover, the death rate was higher in PrBC with CD8+ TILs. The TME of PrBC is characterized by specific patterns of TIL subpopulations with significant biological and prognostic roles. Routine assessment of TILs and TILs subtyping in these patients would be a valid addition to the pathology report that might help identify clinically relevant subsets of women with PrBC.

论文信息

作者
Sajjadi E、Venetis K、Noale M、Azim HA Jr、Blundo C、Bonizzi G、Di Loreto E、Scarfone G
单位
Department of Oncology and Hemato-Oncology, University of Milan, Via Festa del Perdono 7, 20122 Milan, Italy.Italy
文献类型
非美国政府资助研究
期刊
Cells2022 Jul 24
原文标识
PubMed 35892583 · DOI 10.3390/cells11152286